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Abstract
Background: The currently well-established humanized mouse models, namely the hu-PBL-SCID
and SCID-hu systems played an important role in HIV pathogenesis studies. However, despite many
notable successes, several limitations still exist. They lack multi-lineage human hematopoiesis and
a functional human immune system. These models primarily reflect an acute HIV infection with
rapid CD4 T cell loss thus limiting pathogenesis studies to a short-term period. The new humanized
Rag2-/-γc-/- mouse model (RAG-hu) created by intrahepatic injection of CD34 hematopoietic stem
cells sustains long-term multi-lineage human hematopoiesis and is capable of mounting immune
responses. Thus, this model shows considerable promise to study long-term in vivo HIV infection
and pathogenesis.
Results: Here we demonstrate that RAG-hu mice produce human cell types permissive to HIV-1
infection and that they can be productively infected by HIV-1 ex vivo. To assess the capacity of
these mice to sustain long-term infection in vivo, they were infected by either X4-tropic or R5-
tropic HIV-1. Viral infection was assessed by PCR, co-culture, and in situ hybridization. Our results
show that both X4 and R5 viruses are capable of infecting RAG-hu mice and that viremia lasts for
at least 30 weeks. Moreover, HIV-1 infection leads to CD4 T cell depletion in peripheral blood and
thymus, thus mimicking key aspects of HIV-1 pathogenesis. Additionally, a chimeric HIV-1 NL4-3
virus expressing a GFP reporter, although capable of causing viremia, failed to show CD4 T cell
depletion possibly due to attenuation.
Conclusion: The humanized RAG-hu mouse model, characterized by its capacity for sustained
multi-lineage human hematopoiesis and immune response, can support productive HIV-1 infection.
Both T cell and macrophage tropic HIV-1 strains can cause persistent infection of RAG-hu mice
resulting in CD4 T cell loss. Prolonged viremia in the context of CD4 T cell depletion seen in this
model mirrors the main features of HIV infection in the human. Thus, the RAG-hu mouse model
of HIV-1 infection shows great promise for future in vivo pathogenesis studies, evaluation of new
drug treatments, vaccines and novel gene therapy strategies.
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Background
Animal models played an important role in the under-
standing of HIV pathogenesis and in preclinical evalua-
tion of therapeutic strategies [1-4]. In this regard, the
severe combined immunodeficient C.B.-17 SCID/SCID
(SCID) mouse model initially provided an in vivo system
to study murine hemato-lymphoid differentiation and
subsequently was further developed to investigate HIV
pathogenesis [1,3,5-9]. Since these mice are immunodefi-
cient, human cells and tissues can be transplanted without
rejection. Two well-established mouse models have been
used in various studies through the years, namely the hu-
PBL-SCID and SCID-hu mouse models. The hu-PBL-SCID
mouse model is created by injecting human peripheral
blood mononuclear cells intraperitonially. Many elegant
studies on HIV pathogenesis and passive immunity using
monoclonal antibodies were conducted by Mosier and
colleagues [3,5,6]. However, due to the lack of de novo
development of continuously differentiating human cells,
long-term studies on HIV pathogenesis are not possible in
this system.
The second model, the SCID-hu mouse, is created by sur-
gical engraftment of human fetal hematopoietic tissue,
namely thymus and liver, under the kidney capsule of the
SCID mouse [1,4]. Four to six months post-implantation,
a conjoint organ (thy/liv) that resembles human thymus
develops. For as long as one year, these grafts sustain T cell
lymphopoiesis as a predominant feature. Since the SCID-
hu mouse provides an in vivo setting for normal thy-
mopoiesis and HIV preferentially infects CD4 T cells, this
model has been extensively used to investigate AIDS
pathogenesis in the context of a human lymphoid organ.
Many pioneering studies were conducted by McCune and
Zack's groups [7-9]. Early experiments have shown that
infection kinetics follow a dose- and time-dependent
course. Studies with drugs like AZT demonstrated the fea-
sibility of in vivo drug testing and paved the way for other
novel approaches [10,11]. Later investigations elaborated
the detrimental effects of the infection on the various sub-
populations of thymocytes as well as thymic non-T-cell
elements like thymic epithelial cells [8,12]. Viral strain-
specific differences were documented; additionally, the
roles of HIV accessory proteins such as nef in virulence
were ascertained [13,14]. Viral latency could be estab-
lished in this model, thus further expanding its utility
[15,16]. Although the kinetics of CD4 T cell loss differ,
both the SCID-hu and hu-PBL-SCID mouse models sup-
port infection with either of the R5 and X4 HIV-1 viral
strains [14]. In addition to pathogenesis studies, another
innovative exploitation of the SCID-hu mouse model has
been in gene therapy studies [17-20].
Despite these notable successes with the above in vivo
humanized mouse models, several limitations still exist.
Chief among these are that the scope of these models is
primarily limited to the study of an acute HIV infection
lasting only a few weeks due to the rapid decline of sus-
ceptible cell populations and a lack of continual multi-
lineage hematopoiesis providing a constant supply of a
wide spectrum of hematopoietic cells that HIV infects in
the human. Furthermore, there is no functional human
immune system operating in these models, thus limiting
the study of viral pathogenic effects in the absence of an
immune response and precluding immunity studies.
Newer humanized mouse models have recently emerged
that can rectify the above limitations [21-25]. Prominent
among these is the humanized Rag2-/-γc-/- mouse model
(hereafter referred to as RAG-hu) [26-31]. This consists of
a double mutant mouse of an alymphoid phenotype with
defects in the genes encoding recombinase activating gene
2 (Rag2) and common cytokine receptor gamma chain.
The Rag mutation prevents normal maturation of T and B
lymphocytes. Absence of functional receptors for IL-2, IL-
7 and other cytokines prevents the expansion of lym-
phocytes, including that of NK cells which function to
reject foreign grafts. Intravenous administration of human
hematopoietic stem cells together with exogenous admin-
istration of human cytokines leads to a better engraftment
rate. A recent breakthrough of even more extensive
engraftment without exogenous cytokine administration
has been achieved by Manz and colleagues [28]. Intrahe-
patic injection of human CD34 hematopoietic stem cells
into conditioned neonatal mice led to superior and sus-
tained engraftment resulting in de novo multi-lineage
human hematopoiesis with the production of T cells, B
cells and dendritic cells. Formation of structured primary
and secondary lymphoid organs was seen with human
cells engrafting in thymus, bone marrow, spleen and
lymph nodes. Importantly, productive human immune
responses were seen when engrafted mice were immu-
nized with tetanus toxoid and infected with Epstein-Barr
virus. Thus, this model is distinguished from the previous
humanized mouse models by its capacity for multi-line-
age human hematopoiesis and the presence of a func-
tional human immune system. Therefore, the RAG-hu
mouse model offers several advantages for HIV research.
Due to these unique features, we evaluated this new
humanized mouse model for its susceptibility to HIV-1
infection and its utility for pathogenesis studies. In these
proof-of-concept studies we show that RAG-hu mice are
permissive to infection with both R5 and X4 tropic HIV-1,
displaying prolonged viremia and CD4 T cell depletion
characteristic of HIV infection and disease in the human.Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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Results and discussion
Hematopoietic cells differentiated in vivo in humanized 
Rag2-/-γc-/- mice (RAG-hu mice) are susceptible to HIV-1 
infection
Previous studies of Traggiai et al established the multi-lin-
eage human hematopoiesis in CD34 cell reconstituted
Rag2-/-γc-/- mice [28]. To systematically evaluate the utility
of the RAG-hu mouse for HIV-1 infection studies, we first
constructed RAG-hu mice by intrahepatic injection of
human fetal liver-derived CD34+ cells into conditioned
neonatal BALB/c-Rag2-/-γc-/- mice. Our initial experiments
evaluated the transplanted mice to verify the levels of
human cell engraftment, duration of their persistence, tis-
sue distribution, and the presence of HIV-1 susceptible T
cells and monocytes. Human cell engraftment was deter-
mined by FACS analysis of peripheral blood cells after
staining with the human panleukocyte marker CD45
beginning 12 weeks post-injection. Over 150 mice have
been evaluated to date. Of the mice showing detectable
levels of engraftment (97%), the human cell levels ranged
from 5–89%. Over 50% of mice showed >30% engraft-
ment. A representative FACS plot depicting levels of
engrafted CD45 cells is shown in Fig. 1A. We also deter-
mined the duration of engraftment and persistence of
human cells in RAG-hu mice. When the engrafted mice
were analyzed at one year post-engraftment, similar levels
of human hematopoiesis could be seen relative to the lev-
els seen at 12 weeks (Fig 1D and 1E).
To verify the presence of HIV-1 susceptible cells as well as
human immune cells in the engrafted mice, we FACS ana-
lyzed peripheral blood cells to detect T cells and mono-
cytes after staining with appropriate antibodies. T cell
lineage populations staining positive for CD45/CD3+/+
and CD45/CD3/CD4+/+/+ T lymphocytes were detected in
peripheral blood (Fig. 1B) as well as in thymus, spleen
and lymph nodes (data not shown), similar to previous
reports. Human monocytes were found in peripheral
Human cell engraftment in the peripheral blood of CD34 cell-reconstituted Rag2-/-γc-/- mice and duration of engraftment Figure 1
Human cell engraftment in the peripheral blood of CD34 cell-reconstituted Rag2-/-γc-/- mice and duration of 
engraftment. Conditioned neonatal mice were injected with CD34 cells intrahepatically. At different times post-reconstitu-
tion, mice were bled to detect human cell engraftment. Peripheral blood cells were stained with different antibodies after RBC 
lysis and analyzed by FACS. (A) Cells stained with antibodies against the human panleukocyte marker CD45 at 12 weeks post-
engraftment. (B) Cells stained with antibodies against the T cell markers CD3 and CD4. (C) Cells stained with antibodies 
against the monocyte markers CD14 and CCR5. To analyze the duration of engraftment, peripheral blood cells from an 
engrafted mouse were stained with antibodies against CD45 at 12 weeks (D) and 52 weeks (E) post-engraftment.Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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blood displaying characteristic CD45, CD14, and CCR5
markers (Fig. 1C), similar to the markers seen with mac-
rophages originating from CD34 cells differentiated in
vitro [32]. Monocytic cells were also seen in the lymph
nodes and spleen (data not shown). We also assessed the
CD4:CD3 cell ratio by FACS and found it to be similar
(2.3:1) in all organs examined (data not shown) and at
the high end of the normal human range [33]. With
regard to the monocyte populations in the peripheral
blood, the CD14+ cells detected were predominantly of
the CD14lo phenotype. The CD14lo population is typi-
cally associated with high CCR5 expression in human,
which was also the case here in the RAG-hu mice.
To further verify the presence of human T cells in lym-
phoid organs, an engrafted mouse was sacrificed and thy-
mus, spleen, and lymph node sections were stained to
detect the human T cell markers CD3, CD4, and CD8 (Fig.
2). Both CD4 and CD8 positive T cell sub-populations
were detected in each of the three organs, with a high den-
sity of T cells present in the thymus and lymph nodes. T
cells were seen as minor clusters in the spleen. These data
collectively confirmed the successful engraftment of Rag2-
/-γc-/- mice with human CD34 hematopoietic progenitor
cells and their lineage specific differentiation into HIV-1
susceptible human T cells and monocytes.
Before embarking on in vivo infections of these human-
ized mice, we first determined if the human cells matured
in vivo were susceptible to HIV-1 infection ex vivo.
Accordingly, cells obtained from lymphoid organs of
RAG-hu mice, namely thymus, spleen and lymph nodes,
were cultured in vitro and infected with a NL4-3 (X4-
tropic) HIV-1 reporter virus that expresses the murine
CD24 heat stable antigen (HSA). Our results showed pro-
ductive infection of these cells as shown by increasing lev-
els of HIV-1 p24 production at different days post-
Human T cell engraftment in lymphoid organs Figure 2
Human T cell engraftment in lymphoid organs. CD34 cell-reconstituted mice were sacrificed at 19 weeks post-engraft-
ment, and thymus, spleen and lymph nodes were collected. Tissue sections were subjected to immuno-staining with different 
antibodies specific for human T cells as described in methods.Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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infection (Fig. 3). These data indicated that the engrafted
CD34 cells matured into HIV-1 susceptible cells.
RAG-hu mice are permissive for chronic HIV-1 infection
After establishing that RAG-hu mice generate differenti-
ated human cells susceptible to HIV-1 infection, we next
proceeded to evaluate if these mice can be productively
infected in vivo. Mice were infected intraperitoneally with
either HIV-1 X4 tropic NL4-3 (n = 9) or R5 tropic BaL (n
= 5) viruses. In some experiments a HIV-1 strain with a
GFP reporter gene (NLENG1-IRES) was used either alone
(n = 2) or in combination with NL4-3 virus (n = 5) for
infection to facilitate detection of infected cells in periph-
eral blood samples via FACS analysis. Blood samples were
drawn roughly at weekly intervals, and the cellular and
plasma fractions were separated. DNA PCR was used to
detect integrated provirus and RT-PCR was performed to
detect the circulating cell-free virus. A summary of both
types of PCR analyses for viral detection is presented in
Table 1 and a representative agarose gel showing the
amplified PCR products is shown in Fig 4. Select plasma
samples were also analyzed by Q-RT-PCR to determine
HIV-1 viral load. In infected RAG-hu mice, the HIV-1 viral
loads reached as high as 1.2 × 107 copies/ml (Table 1).
However, not all samples could be evaluated due to insuf-
ficient sample volumes and/or the presence of a PCR
inhibitor.
Evidence of virus could be detected by DNA- or RT-PCR in
HIV-1 infected mice (n = 16) for up to 30 weeks post-
infection, the longest time point examined. As expected,
no PCR signal could be detected in either uninfected mice
(n = 4), or unengrafted mice infected with HIV-1 BaL (n =
5). Weekly data was not collected for all the infected mice
as some were sacrificed at an early time point. Similarly,
30 week data is not available for all the mice at this time
as some mice were infected at a later date than the initial
set. Although considerable variability was present in the
level of human cell engraftment in individual mice at the
time of infection, surprisingly, mice with as low as 5%
Ex vivo productive HIV-1 infection in human cells differentiated in reconstituted Rag2-/-γc-/- mice Figure 3
Ex vivo productive HIV-1 infection in human cells differentiated in reconstituted Rag2-/-γc-/- mice. Thymus, spleen 
and lymph node tissues were collected at 16 weeks post-engraftment. Single cell suspensions were made and stimulated for 3 
days with PHA and IL-2, and later challenged with HIV-1 NL4-3 HSA reporter virus. To detect productive viral infection, cul-
ture supernatants were analyzed by p24 ELISA at different days post-infection.Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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engraftment (n = 3) were still able to support viremia. This
indicates that infection could be sustained even in the
context of modest human cell reconstitution.
The in vivo presence of virus in blood up to 30 weeks post-
infection is suggestive of prolonged viremia, which is typ-
ical of the chronic HIV-1 infection seen in the human. In
contrast, in the SCID-hu-PBL model of HIV-1 infection
with the X4-tropic virus, viremia only lasted up to 3 weeks
post-infection in most mice [34]. Persistent viremia in
RAG-hu mice is most likely due to the continual genera-
tion and replenishment of target CD4 T cells from the
engrafted hematopoietic stem cells, in contrast with that
seen in SCID-hu-PBL mice in which virus-depleted cells
are not replenished by endogenous production of T cells.
We also determined whether RAG-hu mice support infec-
tion by R5 tropic HIV-1. Our results have shown produc-
tive infection in all the R5 BaL virus-injected mice. Thus,
either X4 or R5 tropic HIV-1 can establish productive
infection of RAG-hu mice akin to both the SCID-hu and
SCID-hu-PBL mouse models. Although data was not gen-
erated for all time points, the available viral load data is
indicative of high level of R5 virus replication.
To further confirm the PCR-based viremia data, virus re-
isolation from some of the infected animals was per-
formed. Peripheral blood cells obtained from three X4-
infected mice (up to 20 weeks post-infection) and thymo-
cytes and splenocytes from one X4-infected mouse (12
weeks post-infection) were co-cultured with susceptible
SupT1 cells to amplify the virus. The co-cultures were pos-
itive for viral p24 production, thus confirming the pres-
ence of viable infectious virus in infected animals (data
not shown).
As mentioned previously, in some experiments mice were
infected with a GFP reporter HIV-1 to facilitate FACS-
based identification of infected cells biopsied from virus-
injected mice as described above. However, few GFP+ cells
were detected by FACS analysis in either peripheral blood
or lymphoid organs of sacrificed mice (data not shown).
Nevertheless, the GFP virus-infected mice were consist-
Table 1: Detection and quantification of HIV-1 in peripheral blood by PCR
Experiment 1
Mouse Infection 1 w 11 w 24 w 30 w
1 7 C t r l ----
4 0 C t r l ----
1 N+G + n/a n/a n/a
2 N+G + n/a n/a n/a
9 N+G + (369,000)a + + + (31,710)b
16 N+G + (165,000)a + + (12,200,000)a + (81,440)b
2 1 G++++  ( 8 , 8 5 0 ) b
2 4 G++++  ( 1 7 , 2 2 0 ) b
Experiment 2
Mouse Infection 1 w 9 w 14 w 20 w
5 0 C t r l ----
5 1 C t r l ----
63 N + n/a n/a n/a
64 N + + (28,000)a n/a n/a
65 N + n/a n/a n/a
70 N + n/a n/a n/a
56 N+G + (253,000)a + + (52,250)a n/a
71 B + + (436,000)a + + (261,140)b
72 B + + (62,300)a + + (480,770)b
75 B + + (65,230)b n/a n/a
76 B + + (430,280)b n/a n/a
88 B + + (1,305,200)b n/a n/a
DNA PCR and RT-PCR analyses were performed on peripheral blood cells and plasma, respectively from infected RAG-hu mice using primers 
specific to the HIV-1 pol gene. Virus detection by one or both assays at various weeks post-infection is depicted as (+), while a lack of detection by 
both assays is depicted as such (-). Key: Ctrl = uninfected, N = NL4-3, G = NLENG1-IRES, B = BaL, n/a = available (sacrificed), a = viral load 
determined by Amplicor method, b = viral load determined with primers towards the LTR. Quantitative RT-PCR was performed on select samples 
to determine viral load per milliliter of plasma, as indicated in parentheses. Viral loads were initially determined with the Amplicor test (Roche 
Diagnostics). Later samples were analyzed with another primer set towards the HIV-1 LTR [41].Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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ently viremic, thus indicating its replicative capacity in
vivo. Failure to detect large numbers of GFP-positive cells
in infected mice is possibly due to attenuation of this
modified reporter virus as compared to the wild-type
strain (see below).
To further confirm active HIV-1 replication in vivo,
infected mice were sacrificed and lymphoid organs were
analyzed for viral presence in histological sections. In situ
hybridization using an HIV-specific probe was performed
on tissue sections of spleen and thymus (Fig. 5). Infected
cells were readily detected in mouse #64 (X4 infection),
which was sacrificed at 12 weeks post-infection. Quantifi-
cation of HIV-infected cells in these organs revealed 167
positive cells/mm2 in thymus and 0.8 positive cells/mm2
in spleen. As expected, no HIV-positive cells were detected
in an uninfected mouse. These data indicated that HIV-
infected cells are dispersed in various lymphoid organs as
seen in the human.
HIV-1 infection leads to CD4 T cell depletion in RAG-hu 
mice
A central hallmark of HIV infection is the gradual deple-
tion of CD4 T lymphocytes, which are primary targets of
HIV infection. To investigate if this phenomenon is reca-
pitulated in HIV-1 infected RAG-hu mice, the levels of
CD4 T cells in peripheral blood at different times post-
infection were determined. Cells were stained for the pan-
T cell marker CD3 as well as CD4, and the ratio of
CD3+CD4+ to CD3+CD4- was used to measure depletion
of CD4+ T cells as described previously in hu-PBL-SCID
mice HIV infection studies [35]. Baseline ratios in each
mouse were established in pre-bleeds before infection
(mean 70% CD4:CD3 ratio, range 50–85%, n = 24).
Five of seven infected mice exhibited depletion of CD4 T
cells for at least 9 weeks (Fig. 6B–D), whereas none of the
uninfected mice showed any CD4 T cell loss (Fig. 6A).
CD4 T cell depletion was first detected at 3 weeks post-
infection and in one case persisted through at least 24
weeks (mouse #16) as shown in Fig. 6B. On subsequent
analysis at 30 weeks, this mouse continued to display
CD4 T cell depletion at 6% of initial levels (data not
shown). A representative FACS plot showing selective
CD4 T cell loss over a 20 week time period for mouse #16
is shown in Fig. 6E. Interestingly, the only infected mice
not displaying CD4 T cell depletion were those infected
with the GFP reporter virus alone (n = 2) (Fig. 6C). In a
different experiment where mice (n = 3) were infected
with both cell-associated and cell-free GFP reporter virus,
CD4 depletion also did not occur (data not shown). It is
possible that the insertion of the foreign GFP gene into the
NL4-3 genome may have resulted in attenuation of its vir-
ulence. Although capable of causing persistent infection
as assessed by PCR, the GFP virus harboring additional
genomic burden might not be robust enough to produce
CD4 T cell depletion. We noted that some mice (#s 9, 71,
72) exhibited profound CD4 depletion at 6 and 9 weeks
post-infection (to ~20% of initial values), followed by a
rebound of CD4 cells to pre-infection levels. Mouse #16
displayed a more sustained CD4 T cell depletion at 6, 9,
11, 20, 24 and 30 weeks post-infection (up until the last
time point evaluated). The differences and fluctuations in
CD4 T cell depletion levels could be due to different levels
of engraftment and/or the physiological status of each
individual mouse. In any case, future evaluations using
larger numbers of mice will ascertain possible reasons and
mechanisms. CD4 T cell depletion was also observed in
both mice infected with the R5-tropic strain BaL, similar
to the results seen in SCID-hu-PBL mice (Fig. 6D) [35].
The continued CD4 T cell depletion through at least 9
weeks indicates that R5-tropic virus is also pathogenic in
RAG-hu mice. In another ongoing experiment, 2 addi-
tional mice infected with BaL virus and 1 additional
mouse infected with NL4-3 were also found to have CD4
T cell depletion to below 50% of normal at 9 weeks post-
infection.
To further investigate CD4 T cell depletion at the infected
tissue level, thymus from an uninfected control and
infected mouse (same tissues as detailed above for HIV in
situ hybridization) were evaluated by immuno-staining
with CD4 antibodies (Fig. 7). Many CD4 cells were
detected as expected in the uninfected thymus compared
PCR detection of HIV-1 in infected RAG-hu mice Figure 4
PCR detection of HIV-1 in infected RAG-hu mice. 
Peripheral blood was collected from infected mice at differ-
ent weeks post-infection. Cellular and plasma fractions were 
separated by centrifugation. DNA from the cellular fractions 
was subjected to DNA PCR to detect integrated virus (A), 
whereas the RNA extracted from the plasma fraction was 
subjected to RT-PCR to detect cell-free virus (B). Results 
from a representative HIV-1 infected RAG-hu mouse (#16) 
are shown.Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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to that of infected thymus wherein there was a paucity of
these cells. This data adds further evidence for CD4 T cell
depletion as seen in peripheral blood assayed by FACS.
In a recent report Watanabe et al also demonstrated pro-
ductive HIV-1 infection in a humanized mouse system
(hNOG) capable of de novo multilineage human hemat-
opoiesis using a different immunodeficient knock-out
mouse on a NOD-SCID genetic background (NOD/SCID/
IL2-R gamma chain knock-out mouse) [36]. Although
only single time points for viral detection were shown in
this report, high level viremia was seen in conjunction
with CD4 T cell loss reflecting the results we have shown
here. Humoral immune responses to HIV-1 antigens were
also detected in some infected mice. Thus, these data from
hNOG and RAG-hu mice corroborate that CD34 progeni-
tor cell reconstituted mice with multilineage hematopoie-
sis are susceptible to HIV-1 infection. However, a number
of parameters distinguish and differentiate between the
hNOG and our present RAG-hu mouse models of HIV-1
infection. First, since the hNOG model uses mice with a
NOD genetic background, this limits their experimental
life span as these mice are prone to a high incidence of
lymphomas and early death. On the contrary, the RAG-hu
mouse has a normal life span, and sustains human hemat-
opoiesis for more than a year. Second, in the hNOG
model, HIV-1 infection could only be followed until 40
days (presumably due to their short life span) and thus
the results obtained depict essentially an acute HIV-1
infection as seen in the previous SCID-hu and hu-PBL-
SCID mouse models whereas in the RAG-hu system, the
infection is more chronic, lasting 30 weeks (the latest time
point analyzed to date, and likely to extend for more
weeks pending further analysis). Third, although both X4
and R5 HIV-1 strains caused productive infection in
hNOG mice, only the X4 virus infection resulted in CD4
Detection of HIV-1 in infected RAG-hu mouse tissues by in situ hybridization Figure 5
Detection of HIV-1 in infected RAG-hu mouse tissues by in situ hybridization. Thymus and spleen were collected at 
12 weeks post-infection and sections were made from the frozen tissues. In situ hybridization was performed using digoxi-
genin-labeled antisense probes to detect HIV-1 RNA as described in methods. Dark staining cells indicate the presence of HIV-
1.Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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CD4 T cell depletion in peripheral blood of HIV-1 infected RAG-hu mice Figure 6
CD4 T cell depletion in peripheral blood of HIV-1 infected RAG-hu mice. Peripheral blood was collected at different 
weeks post-infection and cells were stained with CD3 and CD4 antibodies and FACS analyzed. To determine the levels of CD4 
T cells in the whole T cell population (stained with the pan T cell marker CD3), CD4:CD3 ratios were determined as 
described in methods. To obtain a baseline CD4:CD3 level for each individual mouse prior to HIV-1 infection, mice were bled 
a minimum of two times before infection. CD4 T cell levels are depicted as a percent of individual mouse baseline levels 
recorded at 1 week pre-infection. Shown are mean uninfected mouse levels (A, n = 4), infection with HIV-1 NL4-3 + NLENG1-
IRES (B), infection with HIV-1 NLENG1-IRES alone (C), and infection with HIV-1 BaL (D). Also shown (E) are representative 
FACS plots from mouse #16 from various time points post-infection indicating the CD3CD4+/+ and CD3CD4+/- populations 
used to calculate the values shown in A-D.
 Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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T cell loss, whereas in the RAG-hu system both the viral
strains caused CD4 T cell depletion. It is unclear why this
difference exists given both the models are capable of
multilineage hematopoiesis. Possible reasons could be
due to the differences in mouse strains used, or alterna-
tively, the R5 strains could also have displayed CD4 T cell
depletion in hNOG mice if the infection was followed
beyond 40 days. Overall, based on the comparisons
above, the RAG-hu mouse model with its capacity for
long-range hematopoiesis and chronic HIV-1 infection
lasting beyond 30 weeks clearly offers several advantages
over the hNOG model for long-term pathogenesis studies.
In summary, we have presented multiple lines of evidence
demonstrating that RAG-hu mice support chronic HIV-1
infection with prolonged viremia when infected with
either X4 or R5-tropic HIV-1 viral strains. The above
proof-of-concept data also showed that viral infection
leads to CD4 T cell depletion. Since prolonged viremia in
the context of CD4 T cell depletion is seen in this model,
many novel experiments are now possible. Different viral
strains from the field can be evaluated for virulence and
newer drugs can be tested for their long-term efficacy. In
addition, the generation of drug resistant escape mutants
can be evaluated during long-term treatment. Since the
RAG-hu mice are shown to be immunocompetent, a thor-
ough evaluation of their ability to generate HIV-specific
humoral and cellular immune responses will be the next
step to exploit this system for vaccine/immunity studies.
Substantiating the potential for immune response to
other antigens, recent results from our laboratory demon-
strated Dengue virus infection and production of neutral-
izing antibody in RAG-hu mice (R. Troyer, J. Kuruvilla and
R. Akkina; unpublished results to be reported elsewhere).
Such experiments are currently underway to detect HIV
immune responses. Furthermore, this model also permits
systematic evaluation of anti-HIV gene therapeutic con-
structs expressed in differentiated T cells and macrophages
originating from gene-transduced CD34 hematopoietic
stem cells [18,37,38]. However, since this promising
humanized mouse model is relatively new, many addi-
tional basic parameters of HIV-1 infection need to be vig-
orously established to realize its full potential in various
future studies.
Conclusion
RAG-hu mice reconstituted with human hematopoietic
stem cells provide the unique features of multi-lineage
human hematopoiesis and a functional human immune
system which are ideal to study HIV pathogenesis in vivo.
Here we showed that both T cell- and macrophage-tropic
HIV-1 strains can cause persistent infection of RAG-hu
mice resulting in CD4 T cell loss. Prolonged viremia in the
context of CD4 T cell depletion seen in this model mirrors
the main features of HIV infection in the human. The fail-
ure of a chimeric virus containing a reporter gene to cause
Evidence for CD4 T cell depletion in HIV-1 infected RAG-hu mouse thymus Figure 7
Evidence for CD4 T cell depletion in HIV-1 infected RAG-hu mouse thymus. Thymus was collected at 12 weeks 
post-infection (from mouse #64) and sections were made from frozen tissues. Tissue sections were subjected to immuno-
staining with antibodies specific for human CD4 T cells as described in methods.
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CD4 T cell loss indicates possible attenuation in vivo.
Thus, this new humanized mouse model of HIV-1 infec-
tion shows great promise as an in vivo experimental tool
for the evaluation of new drug treatments, vaccines and
gene therapies.
Materials and methods
Generation of humanized Rag2-/-γc-/- mice (RAG-hu mice)
Humanized BALB/c-Rag2-/-γc-/- mice were prepared essen-
tially as described by Traggiai et al [28] with the exception
that human fetal liver-derived CD34+ cells were used for
engraftment [17]. After irradiation at 350 rads, 2–3 day
old neonatal mice were injected intrahepatically with 1 ×
106  CD34+  cells. Transplanted mice were screened for
human cell engraftment at 12+ weeks post-reconstitution.
Peripheral blood was collected by tail bleed, and red
blood cells were lysed using the Whole Blood Erythrocyte
Lysing Kit (R&D Systems, Minneapolis, MN) per the man-
ufacturer's protocol. The white cell fraction was stained
with antibodies against the human pan-leukocyte marker
CD45 and FACS analyzed to verify engraftment.
CD34 cells and cell culture
Human fetal liver-derived CD34 cells were purified and
cultured in cytokine media containing IL-3, IL-4 and SCF
as described previously [17]. The SupT1 human lymphoid
cell line was grown in RPMI 1640 (Invitrogen, Grand
Island, NY) supplemented with 10% FBS. RAG-hu mouse-
derived differentiated human hematopoietic cells were
grown in Iscove's modified Dulbecco's medium (Invitro-
gen, Grand Island, NY) supplemented with 10% FBS, PHA
and IL-2.
HIV-1 infection of primary cells in vitro, viral co-culture 
and quantitation
Human cell reconstituted control or infected mice were
sacrificed at different times post-reconstitution/infection.
Tissues, namely bone marrow, thymus, liver, spleen, and
mesenteric lymph nodes were collected and single suspen-
sions were made followed by RBC lysis. Mononuclear
cells (3 × 106) were seeded and cultured as above. After 3
days, cells were infected with HIV-1 strain NL-r-HSAS (an
X4-tropic strain expressing the murine heat stable antigen
CD24) [9] at an MOI of 3. At 0, 2, and 6 days post-infec-
tion, supernatants were taken and assayed for productive
infection by p24 ELISA (Beckman Coulter, Fullerton, CA).
To isolate virus from infected mice by co-culture, 150 μl
heparinized blood was taken by tail-bleed and red blood
cells were lysed. The white blood cells were added to HIV-
1 susceptible SupT1 cells in the presence of IL-2 and PHA,
and supernatants were assayed for the presence of HIV
p24 by ELISA (Beckman Coulter, Fullerton, CA).
HIV-1 infection of humanized Rag2-/-γc-/- mice
To infect human cell reconstituted RAG-hu mice, HIV-1 in
a 100 μl volume was injected intraperitoneally at least 12
weeks after cell engraftment. Mice received either HIV-1
NL4-3 alone (1.2 × 105 i.u.), HIV-1 BaL alone (0.9 × 105
i.u.), HIV-1 NLENG1-IRES (NL4-3 engineered to express
eGFP) [39] (1.6 × 105 i.u.), or a 1:1 mixture of HIV-1 NL4-
3 and HIV-1 NLENG1-IRES at the same concentrations
above. Mice were monitored daily.
PCR analysis
To detect integrated HIV by PCR, DNA was extracted from
a 25 μl cell pellet from peripheral blood using the
QIAamp DNA Blood Kit (Qiagen, Valencia, CA). PCR was
performed using Taq polymerase (Invitrogen, Carlsbad,
CA) using a primer set to amplify a HIV-1 pol gene frag-
ment as described previously [40]. PCR products were
separated on a 2% agarose gel to resolve an expected 199-
bp fragment. To detect cell-free HIV by RT-PCR, RNA was
extracted from 10–70 μl of plasma using the QIAamp
Viral RNA kit (Qiagen, Valencia, CA). cDNAs were pro-
duced with Superscript III reverse transcriptase (Invitro-
gen, Carlsbad, CA) and PCR amplified using HIV-1 pol
primers [40]. Viral load in plasma samples was initially
determined with the Amplicor test (Roche Diagnostics).
Inadvertent use of heparin as an anticoagulant resulted in
some Q-PCR inhibition. Later samples were collected
without heparin and Q-RT-PCR was performed with
another primer set towards the HIV-1 LTR [41].
Flow cytometry
FACS analysis was used to assess human cell engraftment
in peripheral blood and to detect various human hemat-
opoietic cell populations in different lymphoid tissues.
Whole blood was collected in heparinized capillary tubes
then centrifuged to separate plasma from cells, and red
blood cells were lysed as above. To analyze human cells in
different lymphoid organs, single cell preparations were
made followed by RBC lysis. Cell suspensions were
stained with the following antibodies: hCD45-PE, (eBio-
science), hCD4-PECy5, hCD3-PE, hCD14-PE (Caltag)
and hCCR5 (BD Pharmingen). Stained cells were ana-
lyzed using a Coulter EPICS XL-MCL FACS analyzer (Beck-
man Coulter, Fullerton, CA). To measure CD4 T cell
depletion in HIV-1 infected mice, they were tail-bled peri-
odically. Blood cells were stained for CD3 and CD4 mark-
ers to determine CD3:CD4 cell ratios. CD4 T cell levels
were calculated as a ratio of the entire CD3 population
(CD4+CD3+:CD4-CD3+). To establish baseline CD4 T cell
levels, all mice were analyzed twice before infection.
In situ hybridization for HIV-1 RNA
In situ hybridization for HIV-1 RNA and quantification of
frequencies of virus-producing cells was performed on 4-
μm tissue sections from thymus and spleen previously fro-Retrovirology 2006, 3:76 http://www.retrovirology.com/content/3/1/76
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zen in OCT compound (VWR, Denver, CO) of one HIV-1-
infected and one uninfected RAG-hu mouse, as previously
described for human lymphoid tissues [42]. Three sec-
tions were evaluated from each tissue. In situ hybridiza-
tion was performed using digoxigenin-labeled antisense
riboprobes for env, gag, and nef, and detected using nitro
blue tetrazolium/5-bromo-4-chloro-3-indoyl phosphate
(NBT/BCIP). Sections were lightly counterstained with
hematoxylin to enable visualization of nuclei. The
number of virus-producing cells was determined by visual
inspection and manually counting the positively stained
cells on each section. The sum of the total number of
virus-producing cells was divided by the total area of the
tissue sections inspected, as quantified by a computerized
image analysis system (Leica Q5001W Image Analysis,
Leica, Cambridge, UK) to determine the number of HIV-
1-producing cells per mm2 tissue.
Immuno-staining for lymphocyte and macrophage markers
Immuno-staining for human CD3 (Clone UCHT1, BD
Pharmingen, San Diego, CA), CD4 (Clone RPA-T4, BD
Pharmingen), and CD8 (Clone HIT8a, BD Pharmingen)
was performed on 4-μm tissue sections from a RAG-hu
mouse thymus, spleen, and lymph node previously frozen
in OCT compound. Sections were initially fixed in 1%
paraformaldehyde for 20 min., washed in Tris Buffered
Saline (TBS; 0.05 M Tris hydrochloride, 0.15 M NaCl, pH
7.6) and treated with 1% hydrogen peroxide (Sigma, St.
Louis, MO) in TBS to block endogenous peroxidase activ-
ity. Sections were further blocked for 15 min. with Avidin
(Vector Laboratories, Burlingame, CA), washed in TBS,
followed by Biotin (Vector Labs). Sections were stained
using Vector Laboratories' Mouse on Mouse™ staining kit,
according to the manufacturer's instructions. Color detec-
tion was performed with horseradish peroxidase streptavi-
din (Vector Laboratories) with NovaRed (Vector
Laboratories) added as a substrate producing a red-brown
color. Sections were lightly counterstained with hematox-
ylin like above to enable visualization of nuclei. Control
sections were treated with antibody diluent and processed
in parallel.
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